Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL and IL2 Adjuvant Therapy in Melanoma
NCT00200577Phase 3Completed
- Sponsor
- CHU de Nantes
- Start
- May 2005
- Primary completion
- Mar 2012
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of autologous tumor-infiltrating lymphocytes in melanoma, sponsored by CHU de Nantes. Started May 2005; status: completed.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00200577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00200577.